PE20061424A1 - Compuestos triciclicos de base 1,6-dihidro-1-3,5,6-tetraaza-as-indaceno y composiciones farmaceuticas que comprenden los mismos - Google Patents

Compuestos triciclicos de base 1,6-dihidro-1-3,5,6-tetraaza-as-indaceno y composiciones farmaceuticas que comprenden los mismos

Info

Publication number
PE20061424A1
PE20061424A1 PE2006000492A PE2006000492A PE20061424A1 PE 20061424 A1 PE20061424 A1 PE 20061424A1 PE 2006000492 A PE2006000492 A PE 2006000492A PE 2006000492 A PE2006000492 A PE 2006000492A PE 20061424 A1 PE20061424 A1 PE 20061424A1
Authority
PE
Peru
Prior art keywords
dihydro
alkyl
alkenyl
indaceno
tetraaza
Prior art date
Application number
PE2006000492A
Other languages
English (en)
Spanish (es)
Inventor
William J Pitts
James Kempson
Junqing Guo
Charles M Langevine
Scout H Watterson
Steven H Spergel
Jagabandhu Das
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20061424A1 publication Critical patent/PE20061424A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2006000492A 2005-05-10 2006-05-10 Compuestos triciclicos de base 1,6-dihidro-1-3,5,6-tetraaza-as-indaceno y composiciones farmaceuticas que comprenden los mismos PE20061424A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67969205P 2005-05-10 2005-05-10
US11/430,215 US7737279B2 (en) 2005-05-10 2006-05-08 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same

Publications (1)

Publication Number Publication Date
PE20061424A1 true PE20061424A1 (es) 2006-12-17

Family

ID=36808856

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000492A PE20061424A1 (es) 2005-05-10 2006-05-10 Compuestos triciclicos de base 1,6-dihidro-1-3,5,6-tetraaza-as-indaceno y composiciones farmaceuticas que comprenden los mismos

Country Status (15)

Country Link
US (2) US7737279B2 (https=)
EP (1) EP1888584B1 (https=)
JP (1) JP5047164B2 (https=)
AR (1) AR053725A1 (https=)
AT (1) ATE465162T1 (https=)
CY (1) CY1110419T1 (https=)
DE (1) DE602006013816D1 (https=)
DK (1) DK1888584T3 (https=)
ES (1) ES2342976T3 (https=)
PE (1) PE20061424A1 (https=)
PL (1) PL1888584T3 (https=)
PT (1) PT1888584E (https=)
SI (1) SI1888584T1 (https=)
TW (1) TW200718422A (https=)
WO (1) WO2006122137A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737279B2 (en) * 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
CN104592231A (zh) 2008-06-10 2015-05-06 Abbvie公司 新的三环化合物
MX2012002480A (es) 2009-09-03 2012-03-26 Bristol Myers Squibb Co Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer.
PH12012501000A1 (en) 2009-12-01 2013-02-11 Abbvie Inc Novel tricyclic compounds
RU2711869C3 (ru) * 2009-12-01 2022-02-02 Эббви Инк. Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
RU2012132278A (ru) * 2010-01-12 2014-02-20 Ф. Хоффманн-Ля Рош Аг Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
US20110237599A1 (en) * 2010-03-10 2011-09-29 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9518058B2 (en) 2013-08-29 2016-12-13 Bristol-Myers Squibb Company Process for the preparation of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide
US20160264536A1 (en) 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
DK3074400T3 (en) 2013-11-26 2018-01-15 Hoffmann La Roche Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
CA2937616A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
JP6876685B2 (ja) 2015-09-24 2021-05-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Atx阻害剤としての二環式化合物
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
AU2016328436B2 (en) 2015-09-24 2020-05-14 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
BR112017026682A2 (pt) 2015-09-24 2018-08-14 Hoffmann La Roche novos compostos bicíclicos como inibidores de dupla ação de atx/ca
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
EP4011882B1 (en) * 2016-08-15 2025-03-05 Purdue Research Foundation 4-substituted aminoisoquinoline derivatives
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
JP7291077B2 (ja) 2016-12-16 2023-06-14 ヤンセン ファーマシューティカ エヌ.ベー. Jakファミリーのキナーゼの低分子阻害物質
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
BR112023004550A2 (pt) * 2020-10-08 2023-05-02 Unichem Lab Ltd Compostos tricíclicos substituídos
US12064421B2 (en) 2020-11-02 2024-08-20 Boehringer Ingelheim International Gmbh Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
MX2023010642A (es) 2021-03-11 2023-11-28 Janssen Pharmaceutica Nv Lorpucitinib para uso en el tratamiento de trastornos mediados por jak.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR927003044A (ko) 1990-01-11 1992-12-17 크리스토퍼 케이. 미라벨리 Rna 활성과 유전자 발현을 검출하고 조절하는 조성물 및 그 방법
US6147096A (en) 1998-02-26 2000-11-14 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrrolobenzimidazoles for treating inflammatory diseases
TWI271406B (en) * 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
PY0119496A (es) 2000-08-07 2003-11-03 Neurogen Corp Compuestos heterociclicos como ligandos de receptores gabaa
US6933294B2 (en) 2002-04-03 2005-08-23 Bristol-Myers Squibb Company Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same
WO2004075846A2 (en) 2003-02-25 2004-09-10 Bristol-Myers Squibb Company Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7071333B2 (en) 2003-07-30 2006-07-04 Bristol-Myers Squibb Company Triazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
US7799800B2 (en) * 2003-08-14 2010-09-21 3M Innovative Properties Company Lipid-modified immune response modifiers
GB0403635D0 (en) 2004-02-18 2004-03-24 Devgen Nv Pyridinocarboxamides with improved activity as kinase inhibitors
US20050250829A1 (en) 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
ES2377758T3 (es) 2004-11-12 2012-03-30 Bristol-Myers Squibb Company Compuestos tricíclicos basados en tiazolo[4,5-b]piridina imidazo-fusionada y composiciones farmacéuticas que los comprenden
US7557211B2 (en) 2004-11-12 2009-07-07 Bristol-Myers Squibb Company 8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7737279B2 (en) * 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same

Also Published As

Publication number Publication date
ATE465162T1 (de) 2010-05-15
ES2342976T3 (es) 2010-07-20
US8268855B2 (en) 2012-09-18
WO2006122137A1 (en) 2006-11-16
CY1110419T1 (el) 2015-04-29
DE602006013816D1 (de) 2010-06-02
EP1888584B1 (en) 2010-04-21
US20100210629A1 (en) 2010-08-19
JP2008540547A (ja) 2008-11-20
PT1888584E (pt) 2010-06-22
TW200718422A (en) 2007-05-16
JP5047164B2 (ja) 2012-10-10
PL1888584T3 (pl) 2010-09-30
US20060270654A1 (en) 2006-11-30
AR053725A1 (es) 2007-05-16
EP1888584A1 (en) 2008-02-20
DK1888584T3 (da) 2010-08-09
SI1888584T1 (sl) 2010-07-30
US7737279B2 (en) 2010-06-15

Similar Documents

Publication Publication Date Title
PE20061424A1 (es) Compuestos triciclicos de base 1,6-dihidro-1-3,5,6-tetraaza-as-indaceno y composiciones farmaceuticas que comprenden los mismos
PE20030155A1 (es) Azaindoles como inhibidores de quinasas
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
PE20060842A1 (es) Amino-imidazolonas para la inhibicion de b-secretasa
PE20030010A1 (es) Triazolopiridinas como inhibidores de quinasas
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
PE20040759A1 (es) Imidazo-piridinonas sustituidas como inhibidores de la actividad de la enzima dipeptidilpeptidasa-iv
PE20130234A1 (es) Derivados de heteroaril imidazolona como inhibidores de jak
PE20030129A1 (es) Imidazotriazinas
PE20091833A1 (es) Derivados heterociclicos espiro biciclicos o heterociclicos biciclicos, puenteados, de pirazolo [1,5-a]pirimidinas como inhibidores de quinasas raf y metodos para su preparacion
PE20070805A1 (es) Imidazopirazinas como inhibidores de proteinquinasa
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
UY24585A1 (es) Procedimiento para la preparacion de sildenafil
DE60326060D1 (de) Nichtvernetzende pyrroloä2,1-cüä1,4übenzodiazepine als potentielle antitumor-agentien und ihre herstellung
PE20110387A1 (es) Aminotriazolo-piridinas como inhibidores de cinasa
PE20040832A1 (es) Derivados de indolil pirazinona
PE20091085A1 (es) NUEVOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA E IMIDAZO[1,2-b]-PIRIDAZINA
PE20020885A1 (es) Compuestos de quinazol como inhibidores de mmp
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
PE20061354A1 (es) Compuestos 2-amino-4-oxobutil como inhibidores de la dipeptidil peptidas-iv
NZ601687A (en) Azaindoles useful as inhibitors of janus kinases
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
AR045955A1 (es) Compuestos benzoimidazolicos
PE20091451A1 (es) Derivados de imidazol como inhibidores de cinesina (ksp)
PE20131305A1 (es) Compuesto heterociclico y sus usos

Legal Events

Date Code Title Description
FC Refusal